Merck Patent Gmbh

Tioga Pharmaceuticals, Inc.

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft MIT

Matthias Wiesner

Hans-Peter Buchstaller

Oliver Schadt

Christoph Seyfried

Manfred Baumgarth

Frank Zenke

Christian Sirrenberg

Christiane Amendt

Matthias Grell

Simon Lawrence Goodman

Peter Raddatz

Dirk Finsinger

Claus Fittschen

Joachim Gante

Hanns Wurziger

Lars Thore Burgdorf

Guido Melzer

Sabine Bernotat-Danielowski

Horst Juraszyk

Martin Friedlander

Ulrich Lang

Jutta Haunschild

Horst Kessler

Rudolf Gottschlich

Beate Diefenbach

David Bruge

Hans-Markus Bender

Friedrich Rippmann

Joachim M&auml;rz

Dirk Gottschling

Joachim März

Dirk Weber

Georgette Thumshirn

Bernd Neff

The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Methylene urea derivatives

The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition.

Derivatives of asimadoline with covalently bonded acids

The present invention relates to benzimidazole carboxamides of formula I, the use of the compounds of formula I of as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to a patients. 

Benzimidazole carboxamides as raf kinase inhibitors

The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to patients.

Benzimidazole derivatives as raf kinase inhibitors

Methods and compositions for prophylaxis and/or treatment of diseases of the eye of a patient resulting angiogenesis in the eye using antagonists of the integrin receptors &#x3b1;v &#x3b2;and/or &#x3b1;v &#x3b2;. The compositions can be nanoparticles and are administered to the eye by injection into the sclera of the eye.

Methods and compositions for the treatment of diseases of the eye

Methods for the treatment of a disease of the eye of a patient comprising injecting into the vitreous body of the eye a composition comprising a therapeutically effective amount of an &#x3b1;&#x3b2;and/or &#x3b1;&#x3b2;inhibitor sufficient to inhibit angiogenesis and inhibit neovascularization in the treated eye. The &#x3b1;&#x3b2;and/or &#x3b1;&#x3b2;inhibitor being a compound of formula II: as defined herein or a physiologically acceptable salt thereof.

Integrin inhibitors for the treatment of eye diseases

Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumours 

Pyrrole derivatives

The present invention relates to glycinamide derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Glycinamide derivatives as raf-kinase inhibitors

Process for the preparation of integrin inhibitors of the formula (I), in which R, R, R, R, Rand X have the meanings indicated in Claim, and intermediate compounds 

Method for the production of bicyclic aromatic amino acids and intermediate products thereof

Isoquinoline derivatives of the general formula (I) in which X, Y, Z, R, Rand n are as defined in Patent Claim (), and physiologically acceptable salts or solvates thereof, are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammation, tumors, osteoporosis, infections and restenosis after angioplasty or in pathological processes which are maintained or propagated by angiogenesis.

Isoquinoline derivatives

 The invention relates to compounds having formula (I), wherein R, R, R, R, R, R, R, R, Z, m and n have the meaning cited in claim 1, and to the physiologically acceptable salts and solvates which can be used as integrin inhibitors, especially in the prophylaxis and treatment of circulatory diseases, in case of thrombosis, myocardial infarction, coronary heart diseases, arteriosclerosis, osteoporosis, pathologic processes caused or propagated by angiogenesis and in tumor therapy.

Chromenone and chromanone derivatives as integrin inhibitors

Indol-3-yl derivatives

Adhesion receptor antagonists

Growing community of inventors

Seeheim-Jugenheim, Germany

Matthias Wiesner